130 related articles for article (PubMed ID: 6969632)
1. Phase I trial of metoprine in patients with advanced cancer.
Currie VE; Kempin SJ; Young CW
Cancer Treat Rep; 1980; 64(8-9):951-6. PubMed ID: 6969632
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
Lynch G; Currie V; Kemeny N
Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma.
Lynch GR; Gralla RJ; Kelsen DP; Casper ES; Stoopler MB; Golbey RB
Cancer Clin Trials; 1981; 4(3):273-6. PubMed ID: 6974611
[TBL] [Abstract][Full Text] [Related]
4. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
5. A phase of I trial of 4'-epi-Adriamycin.
Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW
Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
7. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
8. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
Vogel CL; Winton EF; Moore MR; Sohner S
Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of IMPY in a twice weekly schedule.
Haas CD; Joseph U; Belt RJ; Hoogstraten B
Cancer Treat Rep; 1981; 65(5-6):439-41. PubMed ID: 7237464
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]